P

Purple Biotech Ltd
TASE:PPBT

Watchlist Manager
Purple Biotech Ltd
TASE:PPBT
Watchlist
Price: 1.2 ILS Market Closed
Market Cap: 21.3m ILS

Net Margin
Purple Biotech Ltd

0%
Current
0%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-3.3m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Purple Biotech Ltd
Glance View

Market Cap
21.3m ILS
Industry
Pharmaceuticals

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

PPBT Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-3.3m
/
Revenue
0
What is the Net Margin of Purple Biotech Ltd?

Based on Purple Biotech Ltd's most recent financial statements, the company has Net Margin of 0%.

Back to Top